Checkpoint Inhibitor CTX-2026 Shows Promising Efficacy in Preclinical Study

Checkpoint Inhibitor CTX-2026 Shows Promising Efficacy in Preclinical Study
Compass Therapeutics' CTX-2026, an antibody targeting the protein BTN3A1, could be therapeutic in ovarian cancer by helping the immune system destroy cancer cells, preclinical data show. The study, "BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells," was published in the journal Science. The body's immune system is responsible for fighting off infections and killing unhealthy cells, including cancer cells. Fundamentally, the immune system must be able to recognize and attack infected or cancerous cells while at the same time not attacking healthy cells. One of the strategies that has evolved to manage this dichotomy is immune checkpoints. Conceptually, checkpoints are biochemical systems for healthy cells to signal to immune cells that they are healthy and should not be destroyed. One of the best-studied checkpoint systems involves the protein PD-1. Cancer cells will often co-opt immune checkpoints to avoid being destroyed by the immune system. As such, therapies that block these checkpoints — such as PD-1 inhibitors — have shown great benefits in the treatment of cancer, since they allow the immune system to more effectively kill cancer cells. Immune checkpoint inhibitors have shown promise in certain cancer types (e.g., lung cancer and melanoma), but responses in other cancer types, including ovarian cancer, have generally been lackluster. One possible explanation for this discrepancy is that different checkpoint systems may be preferentially used by different cancer types. In the new study, researchers from Compass Therapeutics, Moffitt Cancer Center, and The Wistar Institute evaluated a checkpoint system involving the protein BTN3A1. Previous research had indicated that BTN3A1 had immune-regulating functions. The rese
Subscribe or to access all post and page content.